ISSN 2586-0151 (Print)
ISSN 2586-0046 (Online)
Volume 13, Number 2 (2/2017)
Original Article <page. 66-73 >

Comparative Effectiveness of Adjunctive Aripiprazole versus Bupropion Uses to Selective Serotonin Reuptake Inhibitor on the Specific Symptom of Depression : A post-hoc, Multi-Center, Open-Label, Randomized Study

Ga-Won Lee, MD, PhD1;Kwang-Hun Lee, MD, PhD2;Young-Woo Park, MD, PhD3;Jong-hun Lee, MD, PhD4;Bon-Hoon Koo, MD, PhD1;Seung-Jae Lee, MD, PhD5;Hyung-Mo Sung, MD, PhD6; and Eun-Jin Cheon, MD, PhD1;

1;Department of Psychiatry, College of Medicine, Yeungnam University, Daegu, 2;Department of Psychiatry, Dongguk University Gyeongju Hospital, Gyeongju, 3;Department of Neuropsychiatry, Daegu Fatima Hospital, Daegu, 4;Department of Psychiatry, College of Medicine, Daegu Catholic University, Daegu, 5;Department of Psychiatry, Kyungpook National University School of Medicine, Daegu, 6;Department of Psychiatry, College of Medicine, CHA University, CHA Gumi Medical Center, Gumi, Korea

Objective : The purpose of this study was to examine the effects of adjunctive aripiprazole versus bupropion on specific symptoms of depression.

Methods : Data were from 6-week, randomized, prospective, open-label multi-center study in 103 patients with major depressive disorders. Participants were randomized to receive aripiprazole (2.5-10 mg/day) or bupropion (150-300 mg/day) for 6 weeks. Change in four subscales of the 17-item Hamilton Depression Rating Scale (HAM-D17) that capture core depression symptoms was determined, and change in individual HAM-D17 items was also assessed. Changes in three composite subscales-anxiety, insomnia, and drive were also examined.

Results : Within-group change in the four core subscales was large [effect size (ES)=1.30-1.47] and it was similar to that in the HAM-D17 total score. Differences between aripiprazole and bupropion were significant for each of the four core subscales and the HAM-D17 total score favored aripiprazole (p<0.001). On three composite scales, both treatments caused substantial changes in anxiety (within-group ES=1.10 (aripiprazole) vs. 1.00 (bupropion)], insomnia (ES=0.75 vs 0.50), and drive (ES=1.17 vs 1.15).

Conclusion : This results suggested that both aripiprazole and bupropion adjunctive therapies with selective serotonin reuptake inhibitors resulted in significant and clinically meaningful changes in core symptom subscales for depression.

Key words : Aripiprazole;Bupropion;Core symptoms;Depression.

Anxiety and Mood

This Article